SURAKSHA DIAGNOSTIC LTD SURAKSHA NSEPHARMA

Healthcare · Diagnostics & Research · India

https://www.surakshanet.com

Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics testing, including microarray, noninvasive prenatal, quantitative fluorescent polymerase chain reaction, fluorescence in situ hybridization, and karyotyping; and radiology testing that includes X ray, magnetic resonance imaging, computed tomography scan, USG, DEXA scan, OPG, and mammography. The company also provides Cardiology testing services comprises electrocardiogram, echocardiogram, stress test / treadmill test, wireless holter monitoring, colour doppler, peripheral doppler, and pulmonary function test; gastroenterology, such as upper and lower GI endoscopy, sigmoidoscopy, proctoscopy, colonoscopy, and proctosigmoidoscopy; and neurology testing services, including electroencephalogram, electromyography, and nerve conduction velocity test. In addition, the company provides dental, physiotherapy, immunology & rheumatology, eye, fetal care, ENT, and speciality clinics, as well as home doctor visit services. The company was founded in 1992 and is based in Kolkata, India.

Market & Price

Market Cap

₹1,488.47 Cr

Current Price

₹285.80

High / Low (52W)

₹349.95 / ₹227.95

Beta

Valuation

Stock P/E

46.32

Industry PE

37.60

Forward P/E

31.07

PEG Ratio

Book Value

₹44.35

Price to Book

6.44

P/S

4.80

EV/EBITDA

16.55

Dividend Yield

0.17%

Profitability & Returns

ROCE

14.70%

ROE

13.84%

ROA

8.70%

Profit Margin

10.37%

Op Margin

16.47%

EPS (Latest Qtr)

₹1.21

EPS (TTM)

₹6.17

Balance Sheet & Liquidity

Debt/Equity

0.54

Quick Ratio

0.82

Current Ratio

1.05

Debt

₹130.34 Cr

Total Assets

₹448.12 Cr

Current Assets

₹62.58 Cr

Working Capital

₹2.93 Cr

Ownership

Promoter Holding

61.97%

Chg in Prom Hold

FII / Inst Holding

22.15%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹1,586.04 Cr

Total Revenue (TTM)

₹310.41 Cr

EBITDA

₹95.86 Cr

Free Cash Flow

₹7.61 Cr

Operating Cash Flow

₹81.83 Cr

Shares Outstanding

₹5.21 Cr

Gross Margin

88.25%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

17.75%

Profit 5Y

70.31%

Revenue (YoY)

31.20%

Earnings (YoY)

-5.40%

PROS

Compounding revenue at 17.7% over 5 years.
Profit CAGR of 70.3% over 5 years.
Generates positive free cash flow.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	SURAKSHA SURAKSHA DIAGNOSTIC LTD NSEPHARMA	285.80	46.32	₹1,488.47 Cr	0.17%	14.70%	13.84%	17.75%	70.31%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%

Quarterly Results

Figures in INR.

Metric	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	59.51 Cr	65.09 Cr	72.59 Cr	78.73 Cr	77.69 Cr	81.41 Cr
Cost of Revenue	-	6.10 Cr	8.85 Cr	8.75 Cr	8.90 Cr	8.67 Cr	10.16 Cr
Gross Profit	-	53.41 Cr	56.25 Cr	63.84 Cr	69.83 Cr	69.02 Cr	71.25 Cr
Operating Expenses	-	43.10 Cr	44.99 Cr	50.46 Cr	55.65 Cr	55.57 Cr	57.85 Cr
Operating Income	-	10.31 Cr	11.26 Cr	13.38 Cr	14.18 Cr	13.45 Cr	13.41 Cr
EBITDA	-	18.86 Cr	20.00 Cr	24.66 Cr	24.97 Cr	23.78 Cr	25.15 Cr
Interest Expense	-	1.98 Cr	2.06 Cr	2.70 Cr	2.78 Cr	3.16 Cr	3.92 Cr
Pretax Income	-	8.05 Cr	9.21 Cr	12.47 Cr	12.05 Cr	10.06 Cr	9.98 Cr
Tax Provision	-	2.06 Cr	2.04 Cr	3.29 Cr	3.22 Cr	2.82 Cr	3.82 Cr
Net Income	-	6.15 Cr	7.39 Cr	9.40 Cr	8.99 Cr	7.52 Cr	6.28 Cr
Diluted EPS	1.99	1.18	1.42	1.80	1.73	1.44	1.21

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	190.13 Cr	218.71 Cr	252.09 Cr	310.41 Cr
Cost of Revenue	-	27.40 Cr	27.25 Cr	29.52 Cr	36.48 Cr
Gross Profit	-	162.73 Cr	191.46 Cr	222.57 Cr	273.94 Cr
Operating Expenses	-	146.95 Cr	150.49 Cr	174.44 Cr	219.53 Cr
Operating Income	-	15.78 Cr	40.97 Cr	48.13 Cr	54.41 Cr
EBITDA	-	47.48 Cr	72.84 Cr	85.09 Cr	98.56 Cr
Interest Expense	-	9.06 Cr	8.79 Cr	8.39 Cr	12.55 Cr
Pretax Income	-	6.75 Cr	31.45 Cr	41.41 Cr	44.56 Cr
Tax Provision	-	68.30 L	8.33 Cr	10.43 Cr	13.15 Cr
Net Income	-	6.52 Cr	23.63 Cr	31.82 Cr	32.19 Cr
Diluted EPS	4.00	1.25	4.54	5.97	-

Compounded Sales Growth

5 Years:	17.75%
1 Year:	31.20%

Compounded Profit Growth

5 Years:	70.31%
1 Year:	-5.40%

Stock Price Performance

1 Year:	-12.76%
6 Months:	-4.59%
3 Months:	+1.64%
1 Month:	+0.89%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	281.19 Cr	300.20 Cr	333.52 Cr	448.12 Cr
Current Assets	-	68.05 Cr	72.45 Cr	47.15 Cr	62.58 Cr
Cash & Equivalents	-	2.16 Cr	2.52 Cr	2.25 Cr	3.21 Cr
Inventory	-	6.16 Cr	6.68 Cr	8.05 Cr	8.14 Cr
Receivables	-	4.68 Cr	8.87 Cr	13.81 Cr	22.76 Cr
Total Liabilities	-	125.73 Cr	121.06 Cr	123.29 Cr	204.64 Cr
Current Liabilities	-	38.34 Cr	39.41 Cr	42.72 Cr	59.65 Cr
Long Term Debt	-	8.44 Cr	5.18 Cr	2.88 Cr	17.76 L
Total Debt	-	96.87 Cr	90.48 Cr	88.89 Cr	130.34 Cr
Total Equity	-	155.93 Cr	179.41 Cr	211.24 Cr	244.85 Cr
Shares Outstanding	-	5.21 Cr	5.21 Cr	5.21 Cr	5.21 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	44.10 Cr	60.48 Cr	63.36 Cr	81.83 Cr
Investing Cash Flow	-	-20.80 Cr	-35.00 Cr	-39.58 Cr	-52.17 Cr
Financing Cash Flow	-	-24.33 Cr	-25.13 Cr	-24.05 Cr	-28.69 Cr
Capital Expenditure	-	-13.17 Cr	-45.47 Cr	-42.02 Cr	-67.34 Cr
Free Cash Flow	-	30.93 Cr	15.01 Cr	21.34 Cr	14.48 Cr
Net Change in Cash	-	-1.03 Cr	35.74 L	-27.32 L	96.73 L

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	85.6%	87.5%	88.3%	88.2%
Operating Margin %	-	8.3%	18.7%	19.1%	17.5%
Net Margin %	-	3.4%	10.8%	12.6%	10.4%
ROE %	-	4.2%	13.2%	15.1%	13.1%
ROCE %	-	6.5%	15.7%	16.6%	14.0%

Shareholding Pattern

Insiders

61.97%

Institutions

22.15%

Public Float

58.25%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SURAKSHA

No recent headlines available.

SURAKSHA · Healthcare